Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.37 |
| ▸ | ELANE | P08246 | 3/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319672 | 0.87 | OPRM1 (0.37) | SMN1; SMN2TP53MDM2ELANECTSG | |
| SCHEMBL4309714 | 0.77 | ELANE (0.42) | ELANECTSGPRTN3CYP2C19OPRM1 | |
| SCHEMBL17446141 | 0.73 | GSK3A (0.45) | MDM2ELANECTSGPRTN3OPRL1 | |
| SCHEMBL4322743 | 0.72 | CYP2C9 (0.38) | TP53ELANECTSGPRTN3CYP2C19 | |
| SCHEMBL4329563 | 0.70 | CHRM2 (0.36) | TP53MDM2ELANECTSGPRTN3 | |
| SCHEMBL8475159 | 0.65 | TSHR (0.36) | SMN1; SMN2OPRL1GAA | |
| SCHEMBL10994478 | 0.63 | GAA (0.47) | ELANECTSGPRTN3CYP2C19OPRM1 | |
| SCHEMBL4575028 | 0.62 | ALDH1A1 (0.41) | SMN1; SMN2OPRM1GAA | |
| SCHEMBL28316609 | 0.62 | ELANE (0.44) | ELANECYP2C19GAAMEN1KMT2A | |
| SCHEMBL28198953 | 0.61 | CYP3A4 (0.38) | SMN1; SMN2TP53MDM2ELANECYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | SMN1; SMN2 902/4885TP53 570/4885MDM2 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.